Corcept Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CORT Key Statistics
Stock Snapshot
Corcept Therapeutics(CORT) stock is priced at $68.10, giving the company a market capitalization of 7.49B. It carries a P/E multiple of 66.01.
On 2025-11-05, Corcept Therapeutics(CORT) stock moved within a range of $64.50 to $73.69. With shares now at $68.10, the stock is trading +5.6% above its intraday low and -7.6% below the session's peak.
Trading volume for Corcept Therapeutics(CORT) stock has reached 1.13M, versus its average volume of 665.92K.
The stock's 52-week range extends from a low of $49.00 to a high of $117.33.
The stock's 52-week range extends from a low of $49.00 to a high of $117.33.
CORT News
Corcept Therapeutics ( (CORT) ) has released its Q3 earnings. Here is a breakdown of the information Corcept Therapeutics presented to its investors. Elevate Yo...
Earnings Call Insights Corcept anticipates $3B–$5B annual hypercortisolism revenue with relacorilant as FDA decisions near Nov. 04, 2025 7:26 PM ET Corcept Ther...
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earni...
More CORT News
(RTTNews) - Corcept Therapeutics Inc (CORT) released earnings for third quarter that Dropped, from the same period last year but beat the Street estimates. The...
Reports Q3 revenue $207.6M, consensus $218.5M. “The third quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Corcept Therapeutics recently announced new late-breaking data from its pivotal Phase 3 ROSELLA trial at the ESMO 2025 Annual Meeting, revealing that relacorila...
